Koneksa’s unique expertise in designing, developing, and deploying digital health technology (DHT)-enabled biomarkers in clinical trials, and our experience analyzing the corresponding data, can provide value to your product’s journey….
This week, the American Society of Clinical Pharmacology and Therapeutics (ASCPT) held a two-day satellite session dedicated to discussing the challenges of conducting clinical trials in patient populations of limited…
Very often, suboptimal adherence to data collection procedures and/or a study intervention is a cause of a failed clinical trial. Recently, Koneksa’s Chief Scientific Officer, Dr. Elena Izmailova, who is…
“Standing on the shoulders of giants,” as Newton put it, is the foundation of science. That’s especially true in biomarker science, as we take decades of experience with laboratory biomarkers…
Multi-component biomarkers: what are they, and why does it matter? While they are increasingly common in medicine – especially in drug development – there are no “official” definitions yet of…
Koneksa was privileged recently to present at the annual meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT) alongside colleagues from the U.S. Food & Drug Administration (FDA)…
I was delighted to join several of my Koneksa colleagues in person at the recent 13th Summit for Clinical Ops Executives (SCOPE) conference in Orlando, Florida. The focus SCOPE has…
Recently, the FDA released draft guidance for comment on remote digital data acquisition in clinical trials. The applications of digital health technologies (DHT) in clinical trials gained traction over the…
Today, we announced the completion of our Series C financing round, as well as the appointment of industry leader John A. Wagner, M.D., Ph.D. as our first Chief Medical Officer….
© 2026 Koneksa Health. All Rights Reserved.
